Daniel Salvadori - Abbott Laboratories President
| ABT Stock | USD 118.95 0.99 0.84% |
President
Mr. Daniel Gesua Sive Salvadori is Senior Vice President Established Pharmaceuticals, Latin America of the Company. From 2013 to 2014 Chief Executive Officer, Latin America, CFR Pharmaceuticals S.A. . From 2012 to 2013 Executive President, Complex Therapeutics Division, CFR Pharmaceuticals S.A. From 2010 to 2012 Head of Sales and Marketing, Latin America, Sandoz Pharmaceuticals, Novartis AG . From 2009 to 2010 Director of Global Strategy and Mergers and Acquisitions, Sandoz Pharmaceuticals, Novartis AG. since 2017.
| Age | 45 |
| Tenure | 7 years |
| Address | 100 Abbott Park Road, North Chicago, IL, United States, 60064-6400 |
| Phone | 224 667 6100 |
| Web | https://www.abbott.com |
Abbott Laboratories Management Efficiency
The company has Return on Asset of 0.0649 % which means that on every $100 spent on assets, it made $0.0649 of profit. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of 0.1484 %, implying that it generated $0.1484 on every 100 dollars invested. Abbott Laboratories' management efficiency ratios could be used to measure how well Abbott Laboratories manages its routine affairs as well as how well it operates its assets and liabilities. At this time, Abbott Laboratories' Return On Tangible Assets are comparatively stable compared to the past year. Return On Assets is likely to gain to 0.12 in 2024, whereas Return On Capital Employed is likely to drop 0.10 in 2024. At this time, Abbott Laboratories' Non Current Liabilities Other is comparatively stable compared to the past year. Change To Liabilities is likely to gain to about 44.7 M in 2024, whereas Total Current Liabilities is likely to drop slightly above 8.3 B in 2024.Similar Executives
| Showing other executives | PRESIDENT Age | ||
| Richard Kuntz | Medtronic PLC | 63 | |
| Samit Hirawat | Bristol Myers Squibb | 52 | |
| Ann Judge | Bristol Myers Squibb | 58 | |
| Ryan Weispfenning | Medtronic PLC | N/A | |
| Joseph Eid | Bristol Myers Squibb | 52 | |
| Kathryn Wengel | Johnson Johnson | 55 | |
| Sandra Leung | Bristol Myers Squibb | 60 | |
| Carol Surface | Medtronic PLC | 54 | |
| Patrik Jonsson | Eli Lilly and | 57 | |
| Bradley Lerman | Medtronic PLC | 63 | |
| Brian Durkin | AbbVie Inc | 60 | |
| John Elicker | Bristol Myers Squibb | 59 | |
| Aarti Shah | Eli Lilly and | 55 | |
| Louis Schmukler | Bristol Myers Squibb | 65 | |
| Henry Gosebruch | AbbVie Inc | 48 | |
| Johna Norton | Eli Lilly and | 56 | |
| Anat Ashkenazi | Eli Lilly and | 51 | |
| William Chase | AbbVie Inc | 50 | |
| Peter Fasolo | Johnson Johnson | 61 | |
| Frank Chan | Medtronic PLC | N/A | |
| Sean Salmon | Medtronic PLC | 59 | |
Management Performance
| Return On Equity | 0.15 | ||||
| Return On Asset | 0.0649 |
Abbott Laboratories Leadership Team
Elected by the shareholders, the Abbott Laboratories' board of directors comprises two types of representatives: Abbott Laboratories inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Abbott. The board's role is to monitor Abbott Laboratories' management team and ensure that shareholders' interests are well served. Abbott Laboratories' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Abbott Laboratories' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Samuel Scott, Independent Director | ||
| Christopher Scoggins, Senior Vice President - Rapid Diagnostics | ||
| Hubert JD, General VP | ||
| Roger Bird, Senior Vice President - U.S. Nutrition | ||
| Michael Dale, Senior Vice President - Structural Heart | ||
| Sammy Karam, Senior Vice President - Established Pharmaceuticals, Emerging Markets | ||
| Phebe Novakovic, Independent Director | ||
| Roxanne Austin, Independent Director | ||
| Sally Blount, Independent Director | ||
| Daniel Starks, Independent Director | ||
| Michael Pederson, Senior Vice President - Electrophysiology and Heart Failure | ||
| Lisa Earnhardt, Executive Vice President - Medical Devices | ||
| Alejandro Wellisch, Senior Vice President - Established Pharmaceuticals, Latin America | ||
| Robert Alpern, Independent Director | ||
| Glenn Tilton, Independent Director | ||
| Darren McDew, Independent Director | ||
| Christopher Calamari, Senior Vice President - U.S. Nutrition | ||
| Erica Battaglia, VP Officer | ||
| Charles Brynelsen, Senior Vice President - Abbott Vascular | ||
| Hubert Allen, Executive Vice President, General Counsel, Secretary | ||
| Gregory Ahlberg, Senior Vice President - Core Laboratory Diagnostics, Commercial Operations | ||
| Philip Boudreau, Vice President - Finance, Controller | ||
| John Ginascol, Executive Vice President - Core Diagnostics | ||
| Patricia Gonzalez, Independent Director | ||
| Jared Watkin, Senior Vice President - Diabetes Care | ||
| Michael Roman, Independent Director | ||
| Jaime Contreras, Senior Vice President - Core Laboratory Diagnostics, Commercial Operations | ||
| Mary Moreland, Executive Vice President of Human Resources | ||
| Nancy McKinstry, Independent Director | ||
| Andrew Lane, Senior Vice President - Established Pharmaceuticals, Emerging Markets | ||
| Sabina Ewing, Senior Officer | ||
| Randel Woodgrift, Senior Vice President - CRM | ||
| Michelle Kumbier, Independent Director | ||
| John Capek, Executive Vice President - Ventures | ||
| Miles White, Chairman, CEO and Chairman of Executive Committee | ||
| Robert Ford, President, Chief Executive Officer, Chief Operating Officer, Director | ||
| Elaine Leavenworth, VP Officer | ||
| Edward Liddy, Independent Director | ||
| Michael Comilla, Vice Relations | ||
| John Stratton, Independent Director | ||
| Joseph Manning, Senior Vice President - Abbott Nutrition International | ||
| Scott Leinenweber, Acquisitions Licensing | ||
| James Young, VP Officer | ||
| William Osborn, Lead Independent Director | ||
| Louis Morrone, Senior Vice President - Rapid Diagnostics | ||
| Robert Funck, Chief Financial Officer, Executive Vice President - Finance | ||
| Daniel Salvadori, Senior Vice President - Established Pharmaceuticals, Latin America. | ||
| Andrea Wainer, Executive Vice President - Rapid and Molecular Diagnostics | ||
| Melissa Brotz, Vice Marketing |
Abbott Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Abbott Laboratories a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.15 | ||||
| Return On Asset | 0.0649 | ||||
| Profit Margin | 0.14 % | ||||
| Operating Margin | 0.19 % | ||||
| Current Valuation | 211.79 B | ||||
| Shares Outstanding | 1.73 B | ||||
| Shares Owned By Insiders | 0.53 % | ||||
| Shares Owned By Institutions | 77.64 % | ||||
| Number Of Shares Shorted | 12.05 M | ||||
| Price To Earning | 24.14 X |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Abbott Stock Analysis
When running Abbott Laboratories' price analysis, check to measure Abbott Laboratories' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Abbott Laboratories is operating at the current time. Most of Abbott Laboratories' value examination focuses on studying past and present price action to predict the probability of Abbott Laboratories' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Abbott Laboratories' price. Additionally, you may evaluate how the addition of Abbott Laboratories to your portfolios can decrease your overall portfolio volatility.